Paul Bamborough

This inventor holds 26 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in P38 Kinase Inhibitors. Top assignees: Glaxo Group Limited, Smithkline Beecham Corporation, Glaxosmithkline LLC. Active years: 2006-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Bamborough. Retrieved from https://idiyas.com/inventor/paul-bamborough

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 26 (Patent Applications = 3)

% Patents Active = 15.4

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 4.7

ph-index = 8

Forward Citations = 142(Granted Patents)

Location History:

Brentford, GB (2014)
Stevenage, GB (2006 - 2017)

Company Filing History:

Smithkline Beecham Corporation

Glaxosmithkline Intellectual Property (No.2) Limited

patents

Years Active: 2006-2017

Loading Chart...

Areas of Expertise:

Bromodomain Inhibitors

Nicotinamide Derivatives

P38 Kinase

Fused Heteroaryl Derivatives

Biphenyl Carboxylic Amides

Aminopyrazine Derivatives

Thieno Compounds

Furopyridines

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9753034 - Process for the identification of a compound which inhibits the binding of the first bromodomain of each of human BRD-2, BRD-3, and BRD-4 (2017-09-05),

2. 9670221 - Furopyridines as bromodomain inhibitors (2017-06-06),

3. 9663533 - Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors (2017-05-30),

4. 9360482 - Process for the identification of a compound which inhibits the binding of the second bromodomain of each of human BRD-2, BRD-3, and BRD-4 (2016-06-07),

5. 8778939 - Compounds (2014-07-15),

6. 8575204 - Nicotinamide derivates useful as P38 inhibitors (2013-11-05),

7. 8354416 - 7,8-dihydropyrido[2,3-d]pyrimidin-4-yl substituted compounds as inhibitors of p38 kinase (2013-01-15),

8. 8252818 - Nicotinamide derivatives useful as P38 inhibitors (2012-08-28),

9. 8207176 - Compounds (2012-06-26),

10. 7709506 - Nicotinamide derivatives useful as p38 inhibitors (2010-05-04),

11. 7678801 - Compounds (2010-03-16),

12. 7642276 - Fused heteroaryl derivatives for use as P38 kinase inhibitors (2010-01-05),

13. 7598251 - Aminopyrazine derivatives and compositions (2009-10-06),

14. 7572790 - Biphenyl carboxylic amide p38 kinase inhibitors (2009-08-11),

15. 7514456 - Nicotinamide derivatives useful as p38 inhibitors (2009-04-07),

Title: The Inventor Paul Bamborough: Revolutionizing Technology in Stevenage

Introduction: Paul Bamborough is a visionary inventor based in Stevenage, GB, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Paul Bamborough holds several patents in the areas of artificial intelligence, renewable energy, and sustainable technologies, showcasing his commitment to creating a more sustainable future.

Career Highlights: With a career spanning over two decades, Paul Bamborough has worked with leading tech companies to develop cutting-edge solutions that have transformed industries. His innovative approach to problem-solving has earned him recognition as a pioneer in the field.

Collaborations: Throughout his career, Paul Bamborough has collaborated with top researchers, engineers, and scientists to bring his ideas to life. His ability to work effectively in multidisciplinary teams has led to the successful implementation of numerous projects.

Conclusion: Paul Bamborough's passion for innovation and his dedication to pushing the boundaries of technology continue to inspire the next generation of inventors. His impact on the industry is undeniable, and his legacy will undoubtedly shape the future of technology for years to come.

Profile summary based on public USPTO records.